Evidence map›Paper›PMID 38691139›Full record

ArticleEuropean journal of clinical pharmacology2024

Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.

Xueyin Xu, Huanxi Zhang, Longshan Liu, Qian Fu, Chenglin Wu, Xiaobin Lin, Kejing Tang, Changxi Wang, Pan Chen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xueyin Xu *Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Huanxi Zhang *Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Longshan LiuOrgan Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Qian FuOrgan Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Chenglin WuOrgan Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Xiaobin LinDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Kejing TangDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China.
Changxi WangOrgan Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China. wangchx@mail.sysu.edu.cn.
Pan ChenDepartment of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhong Shan Er Lu, Guangzhou, China. chenp73@mail.sysu.edu.cn.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

the Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy Committee CPA-Z05-ZC-2021-003
6 · The paper itself

Abstract

objectivesTo describe the pharmacokinetic (PK) characteristics of nirmatrelvir/ritonavir in renal transplant recipients and explore the potential factors that related to the PK variance of nirmatrelvir/ritonavir and its interaction with calcineurin inhibitor (CNI).

methodsRenal transplant recipients treated with CNI and nirmatrelvir/ritonavir were prospectively enrolled. Steady-state plasma concentrations of nirmatrelvir/ritonavir were determined by high-performance liquid chromatography-tandem mass spectrometry, and the PK parameters were calculated using non-compartmental analysis. Spearman correlation analysis was used for exploring influencing factors.

resultsA total of eight recipients were enrolled; for nirmatrelvir and ritonavir, AUC/dose was 0.24179 ± 0.14495 and 0.06196 ± 0.03767 μg·h·mL

conclusionsThe PK characteristics of nirmatrelvir/ritonavir vary greatly among renal transplant recipients. Factors including Ccr and CYP3A5 genotype were related to the in vivo exposure of nirmatrelvir/ritonavir. During the whole process before and after nirmatrelvir/ritonavir therapy, it is recommended to adjust the CNI basing on renal function to avoid CNI toxicity exposure.

Indexed as

Calcineurin InhibitorsDrug InteractionsKidney TransplantationRitonavirAdultArea Under CurveCytochrome P-450 CYP3AFemaleGenotypeHumansImmunosuppressive AgentsMaleMiddle AgedProspective StudiesTacrolimusTransplant RecipientsCalcineurin InhibitorsCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsRitonavirTacrolimusCalcineurin inhibitorDrug-drug interactionKidney transplantationNirmatrelvir/ritonavirPharmacokinetics

Identifiers

PMID38691139
OpenAlexW4396547578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.